Monocyte and interferon based therapy for the treatment of ovarian cancer

Ovarian cancer is the number one cause of death due to gynecological malignancies, and the fifth leading cause of death due to cancer in women. Patients present late in the course of disease (Stage 3 or 4) as a result of little to no early symptoms and no current non-invasive testing [1]. While surgical debulking and intravenous chemotherapy with intraperitoneal chemotherapy result in an initial remission in disease, approximately 75% of patients will relapse. The relapse is characterized by chemotherapy refractory disease that ultimately becomes chemotherapy resistant.
Source: Cytokine and Growth Factor Reviews - Category: Molecular Biology Authors: Tags: Mini review Source Type: research